纳米药物联合CAR-T疗法在实体肿瘤治疗中的研究进展

Chimeric antigen receptor T cell (CAR-T) therapy has shown remarkable success in treating hematological malignancies. However, CAR-T therapy for solid tumors is still limited due to the unique solid-tumor microenvironment and heterogeneous target antigen expression, which leads to an urgent need of combining other therapies. At present, nano delivery system has become one of the most promising directions for the development of anti-tumor drugs. Based on the background of CAR-T and tumor treatment, we focus on the research progress of nanomedicine combined with CAR-T therapy, and systematically review the strategies and examples in recent years in the aspects of in vivo delivery of mRNA, regulation of tumor microenvironment, combination with photothermal therapy. And we also look forward to the future direction of this filed. .【中文题目：纳米药物联合CAR-T疗法在实体肿瘤治疗中 的研究进展】 【中文摘要：嵌合抗原受体T细胞（chimeric antigen receptor T cell, CAR-T）疗法在血液系统肿瘤治疗中已取得巨大成功，但由于实体肿瘤特殊的肿瘤微环境和缺乏特异性的抗原靶点，CAR-T疗法在实体肿瘤中的治疗效果并不理想，联合其他疗法是目前的迫切需要。当前，纳米递送系统已经成为抗肿瘤药物研发最活跃的方向之一，本文在介绍CAR-T疗法与实体肿瘤治疗相关的背景基础上，重点关注纳米药物联合CAR-T疗法以增强肿瘤治疗的研究进展，从体内递送mRNA、调节肿瘤微环境、联合光热治疗等方面，较为系统地综述了近年来纳米递送系统联合CAR-T疗法的策略与典例，同时对该领域的未来方向进行展望。 】 【中文关键词：纳米递送系统；嵌合抗原受体T细胞疗法；实体肿瘤】.